The Goldman Sachs Group Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Abbott Laboratories (NYSE:ABT) had its target price decreased by The Goldman Sachs Group from $152.00 to $140.00 in a report published on Friday morning,MarketScreener reports. The Goldman Sachs Group currently has a buy rating on the healthcare product maker’s stock.

ABT has been the subject of a number of other research reports. Piper Sandler reduced their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research note on Friday. Jefferies Financial Group boosted their price target on Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. Daiwa Capital Markets upped their price objective on Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $147.00 price objective on shares of Abbott Laboratories in a research report on Thursday, October 16th. Finally, Sanford C. Bernstein boosted their target price on shares of Abbott Laboratories from $150.00 to $154.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $140.79.

Abbott Laboratories Stock Down 1.1%

NYSE:ABT opened at $107.46 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. Abbott Laboratories has a 1-year low of $105.78 and a 1-year high of $141.23. The company has a 50-day moving average of $124.77 and a 200 day moving average of $128.29. The firm has a market cap of $186.86 billion, a PE ratio of 28.89, a price-to-earnings-growth ratio of 1.78 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm posted $1.34 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Hedge Funds Weigh In On Abbott Laboratories

Hedge funds have recently modified their holdings of the stock. Brighton Jones LLC grew its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC raised its stake in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares during the last quarter. Signet Financial Management LLC lifted its position in Abbott Laboratories by 6.5% during the 2nd quarter. Signet Financial Management LLC now owns 3,066 shares of the healthcare product maker’s stock worth $417,000 after acquiring an additional 188 shares during the period. McAdam LLC grew its stake in Abbott Laboratories by 15.7% during the 2nd quarter. McAdam LLC now owns 2,780 shares of the healthcare product maker’s stock valued at $378,000 after purchasing an additional 377 shares during the last quarter. Finally, Register Financial Advisors LLC increased its holdings in shares of Abbott Laboratories by 49.5% in the second quarter. Register Financial Advisors LLC now owns 3,590 shares of the healthcare product maker’s stock valued at $488,000 after purchasing an additional 1,188 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: MedTech and pharma strength, and EPS resilience — Abbott reported adjusted Q4 EPS growth (company highlighted margin improvements) and strong MedTech (+~12%) and Established Pharma (+~9%) performance that partly offset Nutrition weakness; management still projects FY‑2026 adjusted EPS growth. Press Release
• Positive Sentiment: Analysts keep buy/outperform stance despite cuts — several major firms trimmed price targets after the print but largely maintained buy/overweight ratings, signaling conviction in the longer‑term story even as near‑term expectations were tempered. Analyst Reaction
• Positive Sentiment: Some commentators view the pullback as a buying opportunity — market commentators highlight ABT’s dividend history, cash flow and buyback capacity, suggesting the drop may create an attractive entry for long‑term investors. MarketBeat: Pullback Analysis
• Neutral Sentiment: Full earnings call and transcripts available — investors can review management commentary and segment detail in the Q4 earnings call transcript for color on nutrition, diagnostics and Exact/other strategic items. Earnings Transcript
• Neutral Sentiment: Dividend/valuation commentary circulates — value and dividend‑focused outlets are flagging ABT as attractively valued after the pullback; this is background context rather than a near‑term catalyst. Zacks: Value Take
• Negative Sentiment: Revenue miss driven by Nutrition and Diagnostics — Q4 revenue (~$11.5B) fell short of consensus, with Nutrition down sharply (~8–9%) and Diagnostics weak, sparking the initial selloff. Reuters: Revenue Miss
• Negative Sentiment: Guidance slightly below Street — Abbott set Q1 EPS and FY‑2026 EPS ranges that sit near or a touch below consensus, increasing near‑term revenue/growth concerns. Guidance Details
• Negative Sentiment: Multiple price‑target cuts — a raft of firms (Citigroup, Goldman, Raymond James, Sanford Bernstein, Oppenheimer, RBC, etc.) trimmed targets, which can amplify selling pressure even if ratings remain constructive. Benzinga: PT Cuts
• Negative Sentiment: Options and hedging activity spiked — an unusual surge in put buying suggests traders are positioning for further near‑term downside (heightened bearish sentiment).
• Negative Sentiment: Regulatory scrutiny in India — reports of an investigation into alleged misuse of a codeine‑based cough syrup (Abbott Healthcare) add an extra headline risk in emerging markets. Reuters: India Scrutiny

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.